Weight-loss drug semaglutide accelerates recovery from brain inflammation in mice

The diabetes and weight-loss drug semaglutide shows promise in reducing brain inflammation, potentially protecting against cognitive decline. Inflammation in the brain, or neuroinflammation, is a natural defense mechanism that can become chronic and dysregulated, contributing to neurodegenerative conditions like Alzheimer's disease.

Semaglutide, originally developed to treat diabetes and obesity, is a glucagon-like peptide-1 receptor agonist that mimics a natural hormone regulating blood sugar and appetite. Researchers implanted male mice with lipopolysaccharide, a bacterial component that triggers a strong immune response, to study the drug's effects. Some mice were given semaglutide daily for two weeks before the inflammatory challenge.

Microscopic analysis of brain tissue revealed that semaglutide accelerated the recovery process, reducing microglial activation in the hippocampus, a brain region central to learning and memory, 11 days after the inflammatory event. RNA analysis of individual cell nuclei showed that semaglutide reversed inflammatory genetic changes in several non-neuronal cells, including microglia, endothelial cells lining blood vessels, and pericytes maintaining the blood-brain barrier's integrity.

The research suggests semaglutide's protective effect might involve activating specific neurons in the brainstem that produce anti-inflammatory chemical messengers, which then relay protective signals to the rest of the brain's immune and vascular systems. These findings, published in Nature Communications, indicate semaglutide could be a potential treatment for cognitive decline in neurodegenerative diseases.